Published on GHDx (https://ghdx.healthdata.org)

Comparison of Estimated SARS-CoV-2 Seroprevalence through Commercial Laboratory Residual Sera Testing and a Community Survey

General Info

Geography 
United States of America (USA)
Georgia (GEO)
Time period covered 
January, 2020 - December, 2020
Data type
Scientific literature
Keywords 
COVID-19

Citation

Authors 
Bajema KL, Dahlgren FS, Lim TW, Bestul N, Biggs HM, Tate JE, Owusu C, Szablewski CM, Drenzek C, Drobeniuc J, Semenova V, Li H, Browning P, Desai R, Epperson M, Jia LT, Thornburg NJ, Edens C, Fry AM, Hall AJ, Schiffer J, Havers FP
Journal 
Clin Infect Dis
Publication year 
2020
Suggested citation 
Bajema KL, Dahlgren FS, Lim TW, Bestul N, Biggs HM, Tate JE, Owusu C, Szablewski CM, Drenzek C, Drobeniuc J, Semenova V, Li H, Browning P, Desai R, Epperson M, Jia LT, Thornburg NJ, Edens C, Fry AM, Hall AJ, Schiffer J, Havers FP. Comparison of Estimated SARS-CoV-2 Seroprevalence through Commercial Laboratory Residual Sera Testing and a Community Survey. Clin Infect Dis. 2020.
Source URL:https://ghdx.healthdata.org/record/comparison-estimated-sars-cov-2-seroprevalence-through-commercial-laboratory-residual-sera#comment-0